000164643 001__ 164643
000164643 005__ 20230915090554.0
000164643 0247_ $$2pmc$$apmc:PMC9718879
000164643 0247_ $$2doi$$a10.1007/s00115-022-01339-6
000164643 0247_ $$2pmid$$apmid:35670835
000164643 0247_ $$2ISSN$$a0028-2804
000164643 0247_ $$2ISSN$$a1433-0407
000164643 0247_ $$2altmetric$$aaltmetric:129403926
000164643 037__ $$aDZNE-2022-01173
000164643 041__ $$aGerman
000164643 082__ $$a610
000164643 1001_ $$0P:(DE-2719)9000458$$aHaussmann, Robert$$b0$$udzne
000164643 245__ $$aPrognostischer und differenzialdiagnostischer Stellenwert der Liquordiagnostik bei neurodegenerativen Demenzerkrankungen.
000164643 260__ $$aHeidelberg$$bSpringer$$c2022
000164643 3367_ $$2DRIVER$$aarticle
000164643 3367_ $$2DataCite$$aOutput Types/Journal article
000164643 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1671619968_26522
000164643 3367_ $$2BibTeX$$aARTICLE
000164643 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000164643 3367_ $$00$$2EndNote$$aJournal Article
000164643 520__ $$aCerebrospinal fluid (CSF) analysis is an important diagnostic tool in the assessment of dementia. For the differentiation of Alzheimer's disease from other etiologies of dementia syndromes, established biological markers could be helpful to confirm a distinctive neuropathology. Whereas negative CSF findings can rule out the majority of primarily neurodegenerative disorders, overlapping biomarker profiles remain a diagnostic challenge. Therefore, it is important to interpret CSF results within a specific clinical context. Furthermore, atypical CSF data can be challenging and require profound knowledge of preanalytics, biomarker profiles and the broad spectrum of diseases associated with cognitive decline. Beyond the Alzheimer's disease clinical spectrum, current studies aim at investigating CSF biomarkers to better differentiate tauopathies, TDP43(Transactive response DNA binding protein 43 kDa)-proteinopathies and synucleinopathies.
000164643 536__ $$0G:(DE-HGF)POF4-353$$a353 - Clinical and Health Care Research (POF4-353)$$cPOF4-353$$fPOF IV$$x0
000164643 588__ $$aDataset connected to CrossRef, PubMed, , Journals: pub.dzne.de
000164643 650_7 $$2Other$$aAlzheimer’s disease
000164643 650_7 $$2Other$$aCerebrospinal fluid analysis
000164643 650_7 $$2Other$$aFrontotemporal dementia
000164643 650_7 $$2Other$$aLewy body dementia
000164643 650_7 $$2Other$$aNeurodegenerative disease
000164643 650_2 $$2MeSH$$aHumans
000164643 650_2 $$2MeSH$$aAlzheimer Disease: diagnosis
000164643 650_2 $$2MeSH$$atau Proteins: cerebrospinal fluid
000164643 650_2 $$2MeSH$$aPrognosis
000164643 650_2 $$2MeSH$$aNeurodegenerative Diseases: diagnosis
000164643 650_2 $$2MeSH$$aBiomarkers: cerebrospinal fluid
000164643 650_2 $$2MeSH$$aAmyloid beta-Peptides: cerebrospinal fluid
000164643 7001_ $$aHomeyer, P.$$b1
000164643 7001_ $$0P:(DE-2719)2812107$$aBrandt, Daniel Moritz$$b2$$udzne
000164643 7001_ $$0P:(DE-2719)2501739$$aDonix, M.$$b3$$eLast author$$udzne
000164643 773__ $$0PERI:(DE-600)1462945-8$$a10.1007/s00115-022-01339-6$$n12$$p1236-1242$$tDer Nervenarzt$$v93$$x0028-2804$$y2022
000164643 8564_ $$uhttps://pub.dzne.de/record/164643/files/DZNE-2022-01173.pdf$$yOpenAccess
000164643 8564_ $$uhttps://pub.dzne.de/record/164643/files/DZNE-2022-01173.pdf?subformat=pdfa$$xpdfa$$yOpenAccess
000164643 909CO $$ooai:pub.dzne.de:164643$$pdnbdelivery$$pdriver$$pVDB$$popen_access$$popenaire
000164643 9101_ $$0I:(DE-HGF)0$$6P:(DE-2719)9000458$$aExternal Institute$$b0$$kExtern
000164643 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2812107$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b2$$kDZNE
000164643 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2501739$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b3$$kDZNE
000164643 9131_ $$0G:(DE-HGF)POF4-353$$1G:(DE-HGF)POF4-350$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lNeurodegenerative Diseases$$vClinical and Health Care Research$$x0
000164643 9141_ $$y2022
000164643 915__ $$0LIC:(DE-HGF)CCBY4$$2HGFVOC$$aCreative Commons Attribution CC BY 4.0
000164643 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2021-01-28
000164643 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2021-01-28
000164643 915__ $$0StatID:(DE-HGF)3002$$2StatID$$aDEAL Springer$$d2021-01-28$$wger
000164643 915__ $$0StatID:(DE-HGF)0510$$2StatID$$aOpenAccess
000164643 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2021-01-28
000164643 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2022-11-12
000164643 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2022-11-12
000164643 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2022-11-12
000164643 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2022-11-12
000164643 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2022-11-12
000164643 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2022-11-12
000164643 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bNERVENARZT : 2021$$d2022-11-12
000164643 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2022-11-12
000164643 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2022-11-12
000164643 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5$$d2022-11-12
000164643 9201_ $$0I:(DE-2719)1710012$$kClinical Study Team Dresden ; AG Falkenburger$$lClinical Study Team Dresden$$x0
000164643 9201_ $$0I:(DE-2719)1710008$$kAG Donix$$lClinical planning and intersite group$$x1
000164643 980__ $$ajournal
000164643 980__ $$aVDB
000164643 980__ $$aUNRESTRICTED
000164643 980__ $$aI:(DE-2719)1710012
000164643 980__ $$aI:(DE-2719)1710008
000164643 9801_ $$aFullTexts